Barclays
BIOA

Barclays’s BioAge Labs BIOA Stock Holding History

Barclays’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$628K Sell
25,620
-2,620
-9% -$47.3K ﹤0.01% 3085
2026
Q1 		$494K Sell
28,240
-9,540
-25% -$184K ﹤0.01% 3193
2025
Q4 		$500K Buy
37,780
+3,222
+9% +$28.6K ﹤0.01% 3846
2025
Q3 		$203K Sell
34,558
-5,403
-14% -$25.3K ﹤0.01% 4283
2025
Q2 		$165K Buy
39,961
+27,234
+214% +$110K ﹤0.01% 4384
2025
Q1 		$47.9K Sell
12,727
-6,064
-32% -$28K ﹤0.01% 4623
2024
Q4 		$109K Buy
18,791
+6,891
+58% +$119K ﹤0.01% 4574
2024
Q3 		$248K Buy
+11,900
New +$238K ﹤0.01% 4190

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Barclays's BIOA Position: Q2 2026 in Review

Barclays reduced its BioAge Labs (BIOA) stake by 9.3% in Q2 2026, selling an estimated $47.3K and leaving 25,620 shares worth $628K. The position accounts for ﹤0.01% of the portfolio, ranked #3085.

Barclays first reported a position in BIOA in Q3 2024 and has held it in 8 quarters since. 150 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Barclays held 25,620 shares of BioAge Labs worth $628K as of Q2 2026.
  • Barclays sold 2,620 BioAge Labs shares in Q2 2026, an estimated $47.3K.
  • BioAge Labs made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3085 holding.
  • Barclays first reported a position in BioAge Labs in Q3 2024 and has held it in 8 quarters since.
  • 150 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.